Sang J. Shin
Seoul, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 185 publications
Efficacy and safety of cabozantinib plus nivolumab in advanced non-clear cell renal cell carcinoma: a nationwide multicenter study.
Journal: Oncoimmunology
Published: June 29, 2026
Integrative Genomic Analysis Reveals Molecular and Clinical Disparities between Bladder and Upper Tract Urothelial Carcinoma in K-MASTER Program.
Journal: Cancer research and treatment
Published: January 22, 2026
Risk Prediction Based on Clinicopathologic Features in Korean Melanoma Patients by Machine Learning.
Risk Prediction Based on Clinicopathologic Features in Korean Melanoma Patients by Machine Learning.
Journal: Cancer research and treatment
Published: October 22, 2025
PHI-501, a dual inhibitor of RAF and DDR1/2, overcomes MAPK drug resistance in Melanoma.
Journal: Cancer cell international
Published: September 30, 2025
Pan-Asian subgroup analysis of EV-302/KEYNOTE-A39: a phase 3 study to evaluate enfortumab vedotin and pembrolizumab in patients with untreated advanced urothelial carcinoma.
Journal: International journal of clinical oncology
Published: September 16, 2025
Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 07, 2025
Real World Efficacy of 1st-Line Nivolumab Plus Ipilimumab and its Practical Predictive Biomarkers in Advanced Renal Cell Carcinoma: First Analysis from RENOIR Study (KCSG GU22-13).
Journal: Cancer research and treatment
Published: August 08, 2025
Proteomic Profiling of Human Extracellular Vesicles Reveals Diagnostic Biomarkers for Colon Adenocarcinoma.
Journal: Journal of extracellular vesicles
Published: August 04, 2025
A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the combination of atezolizumab with sacituzumab govitecan in patients with locally advanced or metastatic urothelial carcinoma and previously treated with a platinum-based treatment regimen (MORPHEUS-Urothelial Carcinoma).
Journal: ESMO open
Published: July 11, 2025
Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1/2 non-randomized ARTISTRY-1 trial.
Journal: Journal for immunotherapy of cancer
Published: July 01, 2025
Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study.
Journal: The Lancet. Oncology
Published: June 30, 2025
Last Updated: 09/26/2026